Lomass Soliman | Young Researcher Award | Pharmaceutical Sciences

Published on by Network Science

Young Researcher Award

 Lomass Soliman
Affiliation Institute of Pharmaceutical Technology and Regulatory Affairs
Country Hungary
Scoholar ID 6osAAAAJ
Documents 5
Citations 23
h-index 3
Subject Area Pharmaceutical Sciences
Event International Research Awards on Network Science & Graph Analytics

Lomass Soliman
Institute of Pharmaceutical technology and regulatory affairs

 Lomass Soliman The recognition is associated with the International Research Awards on Network Science & Graph Analytics and is intended to highlight emerging researchers whose scholarly activities demonstrate developing expertise, research engagement, and potential for continued contribution to their discipline.

Abstract

This academic recognition profile presents Lomass Soliman in the context of the Young Researcher Award. Soliman is affiliated with the Institute of Pharmaceutical Technology and Regulatory Affairs at the University of Szeged in Hungary and works within the broad field of pharmaceutical sciences. The supplied scholarly indicators record five documents, 23 citations, and an h-index of 3. These metrics describe an emerging publication and citation record and may be considered alongside the quality, originality, relevance, and documented contribution of individual research outputs. Bibliometric indicators are generally most informative when interpreted together with qualitative evidence of scholarly contribution rather than as standalone measures of research quality. [2]

Keywords

  • Lomass Soliman
  • Young Researcher Award
  • Pharmaceutical Sciences
  • Pharmaceutical Technology
  • Regulatory Affairs
  • University of Szeged
  • Research Recognition
  • Bibliometric Indicators

Introduction

Young researcher recognition generally emphasizes the development of an independent scholarly profile, research productivity, methodological competence, and potential for sustained contribution. Within pharmaceutical sciences, research may encompass drug development, pharmaceutical formulation, delivery systems, analytical methods, manufacturing technologies, quality considerations, and regulatory frameworks. The Institute of Pharmaceutical Technology and Regulatory Affairs at the University of Szeged provides an academic setting relevant to these interdisciplinary areas.

Evaluation of early-career researchers benefits from combining quantitative measures with qualitative assessment. Publication counts and citation indicators can provide useful evidence of scholarly visibility, while peer-reviewed research, methodological rigor, originality, reproducibility, and relevance offer additional dimensions for evaluation. [1]

Research Profile

Lomass Soliman’s supplied academic information places the researcher within Pharmaceutical Sciences, with an institutional affiliation in pharmaceutical technology and regulatory affairs. The available Google Scholar identifier is BPP-6osAAAAJ, while the supplied bibliometric record reports five documents, 23 citations, and an h-index of 3. [3]

The combination of pharmaceutical technology and regulatory affairs represents an interdisciplinary research environment in which scientific development can intersect with formulation, product quality, evaluation, and regulatory considerations. Further assessment of the research profile would appropriately consider the specific topics, study designs, venues, and contribution statements associated with the documented publications.

Research Contributions

Based on the supplied information, Soliman’s research profile is situated within pharmaceutical sciences and the institutional domain of pharmaceutical technology and regulatory affairs. The available record supports recognition of an emerging scholarly trajectory rather than a definitive assessment of a specific research breakthrough. Detailed contribution analysis should examine the originality, scientific methodology, reproducibility, and practical or regulatory relevance of individual publications.

  • Development of scholarly activity within pharmaceutical sciences.
  • Engagement with research at the intersection of pharmaceutical technology and regulatory affairs.
  • Establishment of an emerging citation and publication record.
  • Potential for continued interdisciplinary research and professional development.

Publications

The supplied profile reports five scholarly documents associated with the researcher. Individual publication titles, journals, publication years, authorship positions, and DOI identifiers were not provided in the source information supplied for this page. Consequently, specific publications and DOI records should be verified against authoritative bibliographic databases before being added to a formal publication list. This approach avoids attributing publications or identifiers without adequate source verification.

Research Impact

The supplied metrics indicate 23 citations across five documents and an h-index of 3. Citation counts can provide an indication of scholarly uptake, but their interpretation depends on field, publication age, document type, collaboration patterns, and database coverage. [2] For a young researcher, these indicators may be considered as part of a broader assessment that includes research quality, contribution to collaborative projects, methodological development, and prospects for future work.

Award Suitability

Lomass Soliman’s supplied academic profile is consistent with the general concept of a Young Researcher Award because it documents active scholarly work in Pharmaceutical Sciences and an identifiable record of publications and citations. The affiliation with the University of Szeged further establishes an academic research context. Final award eligibility and selection, however, should be determined according to the official criteria of the International Research Awards on Network Science & Graph Analytics and through the event’s formal review process.

Relevant evaluation may include the quality and originality of publications, demonstrated research contribution, academic progression, scholarly visibility, and the potential for continued impact. The current bibliometric indicators can serve as supporting evidence but should not substitute for peer or committee assessment.

Conclusion

Lomass Soliman represents an emerging researcher in Pharmaceutical Sciences affiliated with the University of Szeged in Hungary. The supplied record of five documents, 23 citations, and an h-index of 3 provides a measurable foundation for evaluating early scholarly development.

Within the Young Researcher Award context, the profile may be considered alongside publication quality, research originality, contribution, and future potential. Further bibliographic verification and review of individual research outputs would strengthen a comprehensive assessment.

References

  1. International Committee of Medical Journal Editors. (n.d.). Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals.https://www.icmje.org/recommendations/
  2. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences, 102(46), 16569–16572.https://doi.org/10.1073/pnas.0507655102
  3. Google Scholar. (n.d.). Google Scholar profile: Lomass Soliman, profile ID BPP-6osAAAAJ.https://scholar.google.com/citations?hl=en&user=BPP-6osAAAAJ
  4. University of Szeged. (n.d.). Institute of Pharmaceutical Technology and Regulatory Affairs.https://www.u-szeged.hu/

Dhilshath Shajahan | Best Researcher Award | Drug–Drug Interaction Network

Published on by Network Science

Best Researcher Award

Dhilshath Shajahan
Sri Sairam Engineering College

Dhilshath Shajahan
Affiliation Sri Sairam Engineering College
Country India
Scopus ID 58055495300
Documents 4
Citations 1
h-index 1
Subject Area Drug–Drug Interaction Network
Event International Research Awards on Network Science & Graph Analytics
ORCID 0000-0002-1448-0792

Dhilshath Shajahan is a researcher affiliated with the Mathematics discipline at Sri Sairam Engineering College, India, whose documented scholarly profile includes work associated with drug–drug interaction networks. This research area applies mathematical and network-science concepts to represent relationships among drugs and their potential interactions, supporting structured analysis of complex biomedical information. Network-based approaches have become increasingly relevant to pharmacology because they can represent heterogeneous relationships and provide analytical frameworks for studying interconnected drug systems. [1]

Abstract

This academic recognition profile presents the research activities of Dhilshath Shajahan, affiliated with Sri Sairam Engineering College, India. The researcher’s stated subject area is Drug–Drug Interaction Network, an interdisciplinary field connecting mathematical modeling, graph theory, network science, and biomedical informatics. Drug–drug interaction research seeks to characterize relationships between pharmaceutical agents and identify patterns that may assist in understanding complex medication systems. Graph-based representations are particularly useful because drugs and their interactions can be modeled as nodes and edges, enabling the application of established network measures and analytical methods. [2] The available profile records four documents, one citation, and an h-index of one.

Keywords

Dhilshath Shajahan, Best Researcher Award, Drug–Drug Interaction Network, Network Science, Graph Theory, Biomedical Networks, Drug Interaction Analysis, Mathematical Modeling, Graph Analytics, Pharmacology, Computational Research, Sri Sairam Engineering College, Research Recognition.

Introduction

Drug–drug interactions represent an important research problem because medicines administered together may influence one another through pharmacokinetic, pharmacodynamic, metabolic, or other biological mechanisms. Traditional approaches often examine individual drug pairs, whereas network science provides a broader framework for studying many relationships simultaneously. In a network representation, individual drugs can be treated as nodes and documented interactions as edges, allowing researchers to examine connectivity, centrality, clusters, and other structural characteristics. Such methods have been used in pharmacological and biomedical network research to organize complex relational data. [1][3]

Research Profile

The documented research profile identifies Drug–Drug Interaction Network as the principal subject area. This focus places the work at the intersection of mathematics and computational biomedical research, where graph representations can be used to investigate relationships among pharmaceutical entities. The researcher is affiliated with the Mathematics discipline at Sri Sairam Engineering College. According to the supplied scholarly metrics, the profile includes four indexed documents, one citation, and an h-index of one. These indicators provide a bibliometric snapshot of the recorded research output and should be interpreted in relation to career stage, publication chronology, database coverage, and disciplinary norms. [4]

  • Primary research area: Drug–Drug Interaction Network.
  • Academic discipline: Mathematics and network-oriented analysis.
  • Affiliation: Sri Sairam Engineering College.
  • Country: India.
  • Scopus Author ID: 58055495300.

Research Contributions

Research in drug–drug interaction networks can contribute to the systematic organization and interpretation of interaction data. A mathematical network perspective allows relationships to be analyzed through graph structures rather than as isolated observations. Measures such as degree, betweenness, closeness, community structure, and network density may help identify structurally important drugs or groups of related interactions. Network pharmacology has also demonstrated the value of integrating multiple biological relationships when examining complex therapeutic systems. [2][5]

Within this broader methodological context, the research direction associated with Dhilshath Shajahan is relevant to the development and application of graph-based approaches for biomedical relationship analysis. The combination of mathematical reasoning and drug-interaction data can support reproducible computational studies, comparative network analysis, and the identification of structural patterns that warrant further pharmacological investigation.

Publications

The supplied scholarly profile records four documents associated with Scopus Author ID 58055495300. Because complete bibliographic information, including article titles, journals, publication years, and DOI identifiers, was not supplied, individual publications are not reproduced here to avoid attributing unsupported bibliographic details. The publication record may be verified through the researcher’s indexed author profile and the researcher’s ORCID record. [4][6]

Research Impact

The potential impact of drug–drug interaction network research lies in its ability to provide a structured computational perspective on complex pharmaceutical relationships. Network representations can complement conventional biomedical analysis by enabling researchers to examine interconnected systems and prioritize relationships for further study. Broader network-pharmacology research has shown that graph-based methods can facilitate the integration of heterogeneous biomedical information and support hypothesis generation. [2]

The available bibliometric record reports one citation and an h-index of one. These values represent the indexed record supplied for this profile and should not, by themselves, be interpreted as a complete measure of scholarly quality or future influence. Research impact can also be reflected through methodological contribution, reproducibility, interdisciplinary collaboration, educational value, and subsequent adoption of research findings.

Award Suitability

Dhilshath Shajahan’s research focus is relevant to the Best Researcher Award within the context of the International Research Awards on Network Science & Graph Analytics. The subject area directly connects network science with a biomedical application, providing an interdisciplinary basis for evaluating research involving drug–drug interaction networks. The documented publication record, affiliation, research specialization, and indexed scholarly metrics can be considered as components of an evidence-based assessment. Final award eligibility and selection should remain subject to the official criteria, independent evaluation, and verification of submitted academic records.

  • Alignment with network science and graph-based research.
  • Interdisciplinary relevance to biomedical and pharmaceutical data analysis.
  • Documented scholarly output in an indexed research profile.
  • Potential for continued development of mathematical approaches to biomedical networks.

Conclusion

Dhilshath Shajahan’s documented academic profile reflects an interdisciplinary research direction centered on Drug–Drug Interaction Networks within a mathematical and network-science context. The available record indicates four documents, one citation, and an h-index of one under Scopus Author ID 58055495300. The research area is relevant to contemporary efforts to apply graph-based methods to complex biomedical relationships. Continued publication, collaboration, methodological development, and validation against biomedical datasets may further strengthen the research trajectory and its potential contribution to network-based pharmacological analysis.

References

  1. Vidal, M., Cusick, M. E., & Barabási, A.-L. (2011). Interactome networks and human disease. Cell, 144(6), 986–998.
    https://doi.org/10.1016/j.cell.2011.02.016
  2. Hopkins, A. L. (2008). Network pharmacology: The next paradigm in drug discovery. Nature Chemical Biology, 4, 682–690.
    https://doi.org/10.1038/nchembio.118
  3. Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011). Network medicine: A network-based approach to human disease. Nature Reviews Genetics, 12, 56–68.
    https://doi.org/10.1038/nrg2918
  4. Elsevier. (n.d.). Scopus author details: Dhilshath Shajahan, Author ID 58055495300. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=58055495300
  5. Barabási, A.-L., & Oltvai, Z. N. (2004). Network biology: Understanding the cell’s functional organization. Nature Reviews Genetics, 5, 101–113.
    https://doi.org/10.1038/nrg1272
  6. ORCID. (n.d.). Dhilshath Shajahan: ORCID record. ORCID.
    https://orcid.org/0000-0002-1448-0792

Nikhil Sudhir Sathe | Biological Networks | Best Researcher Award

Published on by Network Science

Dr. Nikhil Sudhir Sathe | Biological Networks | Best Researcher Award

Reliance Life Sciences Pvt Ltd | India

Dr. Nikhil Sudhir Sathe (PhD), currently associated with Laboratory Animal Research Services (LARS), is a distinguished researcher with over 20 years of expertise in drug discovery and preclinical evaluation of new chemical entities. His extensive professional experience encompasses in vitro genotoxicology, cell and microbial culture (aerobic, anaerobic, and viral systems including rabies virus), and small laboratory animal studies. Throughout his career at Reliance Life Sciences, Vimta Labs, Dabur Research Centre, and Wockhardt Research Centre, Dr. Sathe has demonstrated exceptional proficiency in GLP-compliant laboratory practices, including bacterial reverse mutation, chromosomal aberration, micronucleus, ELISA, cytotoxicity, and microbial monitoring assays. His early research contributions involved innovative in vitro models for evaluating the efficacy of antimicrobial and cosmetic products. Academically, he holds a Master’s and Bachelor’s degree in Microbiology from Shivaji University, Kolhapur, both with distinction. Dr. Sathe has contributed significantly to scientific literature with publications in reputed journals such as Vaccine, Microbial Pathogenesis, Infectious Medicine, and BioMed, focusing on bacteriophage therapy and vaccine development against multidrug-resistant pathogens and SARS-CoV-2. His scholarly achievements are complemented by active participation in national conferences and workshops, reflecting his deep commitment to advancing microbiological and biomedical research.

Profiles: Scopus | Orcid | Google Scholar

Featured Publications

"Unveiling Lytic Bacteriophages as Promising Biotherapeutics for the Control of Multidrug-Resistant Pseudomonas aeruginosa", CS Nikhil Sathe, Eugene Athan, Arnab Kapat, BioMed, 2025.

"Safety, immunogenicity and efficacy of Relcovax®, a dual receptor binding domain (RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2 virus", N Sathe, S Shaikh, M Bhavsar, L Parte, A Gadiparthi, S Kad, S Sensarma, Vaccine, 2024.

"Bacteriophage vB_kpnS-Kpn15: Unveiling its potential triumph against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae-Unraveling efficacy through innovative", N Sathe, C Suphioglu, E Athan, A Kapat, Microbial Pathogenesis, 2024.

"Pseudomonas aeruginosa: Infections and novel approaches to treatment “Knowing the enemy” the threat of Pseudomonas aeruginosa and exploring novel approaches to treatment", N Sathe, P Beech, L Croft, C Suphioglu, A Kapat, E Athan, Infectious medicine 2, 2023.

"Development of a novel therapy using bacteriophages: An alternative to antibiotics", NS Sathe, Deakin University, 2023.

Vijaykumar Nimbarte | Medicinal Chemistry | Best Researcher Award

Published on by Network Science

Dr. Vijaykumar Nimbarte | Medicinal Chemistry | Best Researcher Award

BITS Pilani Hyderabad Campus | India

Author Profiles

Scopus

Google Scholar

Early Academic Pursuits

Dr. Vijaykumar Nimbarte began his academic journey with a Bachelor’s degree in Pharmaceutical Sciences from Nagpur University, India, where he acquired foundational knowledge in pharmaceutics, pharmacology, pharmaceutical chemistry, and pharmacognosy. He further advanced his expertise with an M.S. in Medicinal and Pharmaceutical Chemistry from NIPER Hyderabad, India, focusing on the design, synthesis, and biological evaluation of novel soluble epoxide hydrolase inhibitors with anti-inflammatory potential. During this period, he received the NIPER research assistantship and GPAT fellowship and participated in multiple drug discovery workshops, laying a strong foundation in medicinal chemistry. His Ph.D. at Goethe University, Germany, under the Marie Curie Early Stage Researcher Fellowship, focused on the design, synthesis, and evaluation of novel c-MYC G-Quadruplex stabilizing agents, earning him the highest distinction (magna cum laude).

Professional Endeavors

Following his Ph.D., Dr. Nimbarte expanded his research expertise through several key roles in international academic and industrial settings. He worked as a Project Associate in France at the University of Le Havre, where he developed azaindole-based compounds for anticancer activity. At CSIR-IICT Hyderabad, he contributed to synthesizing PBD-based intercalating agents and novel tubulin polymerase inhibitors. Most recently, he served as a Post-Doctoral Scientist at the Max Planck Institute for Medical Research, Germany, where he focused on structure-based drug design for peripheral neuropathy, collaborating with international research centers to optimize CNS-restricted drug candidates. Since January 2024, he has been an Assistant Professor of Medicinal Chemistry at BITS Pilani, Hyderabad, India.

Contributions and Research Focus

Dr. Nimbarte’s research primarily revolves around medicinal chemistry, structure-based drug design, chemical biology, and the development of biologically active small molecules. His work spans multistep organic synthesis, isotope labeling, and characterization using NMR, Mass, IR, and UV techniques. He has actively contributed to designing compounds that stabilize G-Quadruplex DNA structures, targeting cancer, and developing peripheral-restricted CNS drug candidates, addressing blood-brain barrier permeability issues. He has also applied advanced computational methods, including Schrodinger and ChemAxon software, to improve the efficiency and specificity of drug design.

Impact and Influence

With over 10 years of academic-industrial research experience, Dr. Nimbarte has significantly influenced the field of medicinal chemistry. His projects have successfully transitioned from conceptual design to lead candidate development, demonstrating his ability to combine theoretical design with practical synthesis and biological evaluation. He has collaborated internationally, mentored graduate students, led small group teaching sessions, and contributed to scientific knowledge through presentations and publications.

Academic Citations and Publications

Dr. Nimbarte has published more than 17 research papers in reputable international medicinal chemistry journals, including ChemMedChem. He has served as a potential reviewer for multiple journals such as Medicinal Chemistry Research, Bioorganic and Medicinal Chemistry Letters, Bioorganic Chemistry, and Current Medicinal Chemistry, reflecting his recognition as an expert in his field.

Legacy and Future Contributions

Dr. Nimbarte’s legacy lies in bridging the gap between academic research and practical drug discovery through innovative medicinal chemistry approaches. His work on G-Quadruplex stabilizing agents and peripherally restricted CNS drugs has paved the way for safer, more effective therapeutic candidates. Looking forward, his focus will likely continue on designing targeted small molecules with high therapeutic potential while mentoring the next generation of scientists and expanding interdisciplinary collaborations.

Conclusion

Dr. Vijaykumar Nimbarte exemplifies the integration of deep scientific knowledge, practical drug discovery experience, and academic mentorship. His early academic achievements, international research exposure, and impactful publications reflect a career dedicated to advancing medicinal chemistry. Through his innovative approaches, collaborative ethos, and commitment to teaching, he continues to make significant contributions to both the scientific community and future generations of researchers.

Notable Publications

“Understanding the Impact of Calcineurin Inhibitors on T Cell Regulation: Mechanisms and Clinical Implications" 

  • Author: VD Nimbarte, SS Sonak, S Ishwarkar
  • Journal: Critical Reviews
  • Year: 2025

"Modulation of T Cell Regulation by Interleukin-2 Agonists: Mechanisms and Clinical Implications" 

  • Author: SS Sonak, S Ishwarkar, C Nimbarte, VD Nimbarte‏
  • Journal: Critical Reviews
  • Year: 2025

"Synthesis and in Vitro Evaluation of Novel 5‐Nitroindole Derivatives as c‐Myc G‐Quadruplex Binders with Anticancer Activity" 

  • Author: VD Nimbarte, J Wirmer‐Bartoschek, SL Gande, I Alshamleh, M Seibert
  • Journal: ChemMedChem
  • Year: 2021

"Synthesis and Biological Screening of New Lawson Derivatives as Selective Substrate‐Based Inhibitors of Cytochrome bo3 Ubiquinol Oxidase from Escherichia coli" 

  • Author: I Elamri, M Radloff, KF Hohmann, VD Nimbarte, HR Nasiri, M Bolte‏
  • Journal: ChemMedChem‏
  • Year: 2020

"Anti-tyrosinase, anti-cholinesterase and cytotoxic activities of extracts and phytochemicals from the Tunisian Citharexylum spinosum L.: Molecular docking and SAR analysis" 

  • Author: I Saidi, VD Nimbarte, H Schwalbe, P Waffo-Teguo, AH Harrath, L Mansour
  • Journal: Bioorganic Chemistry
  • Year: 2020